Table 4.
Various other types of peptide–drug conjugates in clinical trials.
| peptide | cytotoxic agent | linker | drug release mechanism | target | name | CCTa | reference |
| CNGRCG | hTNFα (Protein) | – | amidases | CD13 receptor | NGR015 | phase III | [113] |
| polyglutamic acid | PTX (SM)b | – | esterases | – | CT2103 | phase III | [114] |
| LHRH | CLIP71c (lytic peptide) | – | amidases | LHRH-R | EP-100 | phase I | [115] |
| DRDDS (spacer) | DAVBLHd (SM)b | 2-mercapto- ethanol | glutathione | folate receptor | EC145 | phase III | [116] |
| D-γ-E-γ-E-γ-E-E (masking moiety) | 12ADTe-Asp | – | PSMA | PSMA | G-202 | phase II | [117] |
aCCT = current clinical trials; bSM = small molecule; cCLIP71 = KFAKFAKKFAKFAKKFAK; dDAVBLH = desacetyl vinblastine hydrazide; e12ADT = 8-O-(12-aminododecanoyl)-8-O-debutanoyl thapsigargin.